Director

Kimberly J. Popovits

Director·10x Genomics, Inc.

About

Kimberly J. Popovits has served on the 10x Genomics board of directors since March 2020.

She was President and Chief Executive Officer of Genomic Health from January 2009 and Chairman of the Board from March 2012 until its acquisition by Exact Sciences in November 2019, having earlier served as the company's President and Chief Operating Officer from February 2002 to January 2009. From November 1987 to February 2002 she held various roles at Genentech, most recently Senior Vice President, Marketing and Sales, and earlier was Division Manager, Southeast Region, for American Critical Care.

She holds a B.A. in Business from Michigan State University.

Since 2020
Age 67
Tenure 6 yrs

Also at 10x Genomics, Inc.

SS Serge Saxonov Chief Executive Officer and Director BH Benjamin J. Hindson Chief Scientific Officer, President and Director JS John R. Stuelpnagel Chairman of the Board of Directors AM Alan Mateo Director ST Sarah Teichmann Director SK Sri Kosaraju Director

Roles

Organization Role Dates Details
10x Genomics, Inc. Director 2020–present Current role
Genomic Health President and CEO (Chairman from March 2012) January 2009 - November 2019 Acquired by Exact Sciences in November 2019.
Genomic Health President and Chief Operating Officer February 2002 - January 2009
Genentech Various roles, most recently Senior Vice President, Marketing and Sales November 1987 - February 2002 SVP Marketing and Sales from February 2001 to February 2002; VP, Sales from October 1994 to February 2001.
American Critical Care (Division of American Hospital Supply) Division Manager, Southeast Region Supplier of healthcare products to hospitals.

External roles

Organization Role Dates
Kiniksa Pharmaceuticals, Ltd. Director February 2018 -
Exact Sciences Director January 2025 -
Talis Biomedical Corporation Director (also interim CEO August 2021 - November 2021) March 2020 - March 2025
MyoKardia, Inc. Director
ZS Pharma Inc. Director

Related

Source: 10x Genomics, Inc. proxy statement (SEC Schedule 14A)

Where the filing does not disclose a value, this page states "Not disclosed" rather than estimating. Smaller filers are exempt from disclosing metric targets and achievement, and larger filers may omit forward targets for competitive reasons.

See how VectorShift works for your firm

Request Demo